Retrospective analysis shows ctDNA positively correlates with recurrence-free survival in early-stage uterine cancer, highlighting its potential as a prognostic biomarker.
Key Points
ctDNA positivity significantly reduces recurrence-free survival rates after surgery, indicating an important risk factor.
Patients with early-stage uterine cancer who were ctDNA-positive before recurrence had a hazard ratio of 25.4 for reduced survival.
This analysis utilizes a personalized ctDNA assay, showing its feasibility for monitoring postoperative patients in clinical settings.
Incorporating ctDNA analysis with traditional risk factors may enhance personalized treatment strategies for patients.